NCT03255408 Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia
| NCT ID | NCT03255408 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | University of Calgary |
| Condition | Obstructive Sleep Apnea of Adult |
| Study Type | INTERVENTIONAL |
| Enrollment | 12 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2027-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 12 participants in total. It began in 2023-01-01 with a primary completion date of 2027-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A prospective double blind, placebo-controlled, randomized cross-over trial to evaluate the effect of lowering cerebral blood flow on the ventilatory chemoreflexes (acute hypoxic and hypercapnic ventilatory responses).
Eligibility Criteria
Inclusion Criteria: * Healthy adults * 18 - 45 years of age * Living in Calgary for the past one year * Have no medical condition or should not be taking any blood pressure medications. * The participant should not be lactose intolerant Exclusion Criteria: * Cerebrovascular, cardio-respiratory, renal and metabolic diseases * Bleeding disorders and upper gastrointestinal diseases e.g. peptic ulcer disease * Pregnancy, obese and sleep-disordered breathing * Drug allergies to non-steroidal anti-inflammatories * Currently smoking
Frequently Asked Questions
Who can join the NCT03255408 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Obstructive Sleep Apnea of Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03255408 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT03255408 currently recruiting?
Yes, NCT03255408 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Calgary to inquire about joining.
Where is the NCT03255408 trial being conducted?
This trial is being conducted at Calgary, Canada.
Who is sponsoring the NCT03255408 clinical trial?
NCT03255408 is sponsored by University of Calgary. The trial plans to enroll 12 participants.